| Oncogenic driver mutations in non-small cell lung cancer: Past, present and future M Chevallier, M Borgeaud, A Addeo, A Friedlaender World Journal of Clinical Oncology 12 (4), 217, 2021 | 229 | 2021 |
| Novel targets for immune-checkpoint inhibition in cancer M Borgeaud, J Sandoval, M Obeid, G Banna, O Michielin, A Addeo, ... Cancer treatment reviews 120, 102614, 2023 | 50 | 2023 |
| Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer-A Systematic Review M Borgeaud, K Parikh, GL Banna, F Kim, T Olivier, X Le, A Addeo Journal of Thoracic Oncology, 2024 | 24 | 2024 |
| The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma M Borgeaud, F Kim, A Friedlaender, F Lococo, A Addeo, F Minervini Journal of clinical medicine 12 (5), 1757, 2023 | 8 | 2023 |
| Immunotherapy in Urological, Gynecological and Gastrointestinal Cancers–Current Landscape M Borgeaud, MG Courtes, P Tsantoulis, A Bodmer, I Labidi-Galy, ... Praxis, 2023 | 4 | 2023 |
| The rapidly changing treatment landscape of systemic therapy for HER-2 positive metastatic breast cancer L Russo-Vorms, C Astaras, J Sandoval, M Borgeaud, A Bodmer healthbook TIMES Oncology Hematology 9 (3), 16-23, 2021 | 2 | 2021 |
| 24P EGFR PACC mutations occur more frequently in compound than classical mutations with improved responses to TKIs X Le, M Stamboulian, M Borgeaud, M Nilsson, S Heeke, A Ravichandran, ... ESMO Open 9, 2024 | 1 | 2024 |
| Management of stage III non-small-cell lung cancer: rays of hope F Kim, M Borgeaud, A Addeo, A Friedlaender Exploration of Targeted Anti-tumor Therapy 5 (1), 85, 2024 | 1 | 2024 |
| Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer. D Tavernari, M Borgeaud, X Liu, P Kaushal, X Le, G Ciriello, A Addeo Journal of thoracic oncology, 2024 | 1 | 2024 |
| Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back A Mariniello, M Borgeaud, M Weiner, D Frisone, F Kim, A Addeo BioDrugs, 1-21, 2025 | | 2025 |
| Dormant Tumor Cells: Current Opportunities and Challenges in Clinical Practice E Boydell, M Borgeaud, P Tsantoulis Onco 5 (1), 3, 2025 | | 2025 |
| Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report D Tavernari, M Borgeaud, X Liu, K Parikh, X Le, G Ciriello, A Addeo Journal of Thoracic Oncology, 2024 | | 2024 |
| EP. 12F. 03 Trametinib in the Treatment of Patients with Metastatic Lung Adenocarcinoma Harboring NF1 Mutation F Kim, M Borgeaud, C De Vito, P Tsantoulis, A Addeo Journal of Thoracic Oncology 19 (10), S655-S656, 2024 | | 2024 |
| P3. 06D. 07 Liquid Biopsy: Exploration of its Added Value in a Daily Practice M Weiner, M Borgeaud, C De Vito, A Addeo Journal of Thoracic Oncology 19 (10), S324-S325, 2024 | | 2024 |
| Rates of febrile neutropenia and its causes in the real world M Borgeaud, S Perano, A Addeo, P Tsantoulis Future Oncology 20 (29), 2203-2212, 2024 | | 2024 |
| 30P Uncommon EGFR kinase domain mutations and responses to EGFR inhibitors: A systematic review M Borgeaud, K Parikh, GL Banna, F Kim, T Olivier, X Le, A Addeo ESMO Open 9, 2024 | | 2024 |
| Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer M Borgeaud, A Friedlaender, A Addeo Translational Lung Cancer Research 12 (11), 2353, 2023 | | 2023 |
